Targeting activated IL-23 signaling in Scleroderma by tildrakizumab
Priyanka Verma, Roberta M Goncalves, Swarna Bale, Jenna Silverman, Timothy Hamill, Kris Shah, Bharath Yalavarthi, Dibyendu Bhattacharyya, Swati Bhattacharyya, John Varga
This study investigates the role of IL-23 in systemic sclerosis (SSc) and shows that tildrakizumab reduces fibrosis in experimental models.
bioRxiv · Feb 2, 2026 · PreprintImmunology